Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BMY 
Bristol-Myers Squibb Company (BMY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: BMY (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
27 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $57.1
1 Year Target Price $57.1
| 4 | Strong Buy |
| 4 | Buy |
| 18 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -1.2% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 94.33B USD | Price to earnings Ratio 17.27 | 1Y Target Price 57.1 |
Price to earnings Ratio 17.27 | 1Y Target Price 57.1 | ||
Volume (30-day avg) 27 | Beta 0.39 | 52 Weeks Range 38.08 - 62.65 | Updated Date 06/30/2025 |
52 Weeks Range 38.08 - 62.65 | Updated Date 06/30/2025 | ||
Dividends yield (FY) 5.35% | Basic EPS (TTM) 2.68 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 11.38% | Operating Margin (TTM) 31.57% |
Management Effectiveness
Return on Assets (TTM) 7.24% | Return on Equity (TTM) 31.99% |
Valuation
Trailing PE 17.27 | Forward PE 6.89 | Enterprise Value 133782995543 | Price to Sales(TTM) 1.98 |
Enterprise Value 133782995543 | Price to Sales(TTM) 1.98 | ||
Enterprise Value to Revenue 2.81 | Enterprise Value to EBITDA 8.26 | Shares Outstanding 2035079936 | Shares Floating 2031234507 |
Shares Outstanding 2035079936 | Shares Floating 2031234507 | ||
Percent Insiders 0.07 | Percent Institutions 82.19 |
Analyst Ratings
Rating 5 | Target Price 57.1 | Buy 4 | Strong Buy 4 |
Buy 4 | Strong Buy 4 | ||
Hold 18 | Sell - | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
Bristol-Myers Squibb Company
Company Overview
History and Background
Bristol-Myers Squibb was formed in 1989 through the merger of Bristol-Myers and Squibb Corporation. Bristol-Myers traces its roots to 1887, and Squibb to 1858. The company has grown through internal development and acquisitions, becoming a major player in the pharmaceutical industry.
Core Business Areas
- Oncology: Focuses on the development and commercialization of therapies for various cancers, including solid tumors and hematological malignancies.
- Hematology: Deals with blood disorders and related conditions, offering treatments for diseases like lymphoma and myeloma.
- Immunology: Develops treatments for immune-mediated diseases, targeting conditions like rheumatoid arthritis and psoriasis.
- Cardiovascular: Provides therapies for cardiovascular diseases, including treatments for heart failure and stroke prevention.
Leadership and Structure
Bristol-Myers Squibb is led by a CEO and a senior management team. The organizational structure is typically divided into business units based on therapeutic areas, supported by functional departments such as R&D, marketing, and finance.
Top Products and Market Share
Key Offerings
- Opdivo: A PD-1 immune checkpoint inhibitor used in the treatment of various cancers. Competitors include Keytruda (Merck) and Tecentriq (Roche). Opdivo generated $8.4 billion in revenue in 2023. Market Share is estimated to be ~25-30% of the PD-1 inhibitor market.
- Eliquis: An anticoagulant used to prevent blood clots in patients with atrial fibrillation and other conditions. Eliquis generated $12.2 billion in revenue in 2023. Competitors include Xarelto (Bayer/Johnson & Johnson).
- Revlimid: A treatment for multiple myeloma and other hematological malignancies. Revlimid generated $9.9 billion in revenue in 2023 before losing exclusivity. Competitors now include generic versions and other MM therapies such as Darzalex (Janssen/Johnson & Johnson).
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, strict regulatory requirements, and increasing competition. It's influenced by factors like an aging global population, rising healthcare costs, and advancements in biotechnology.
Positioning
Bristol-Myers Squibb is a major global pharmaceutical company with a strong presence in oncology, hematology, and immunology. Its competitive advantages include a robust pipeline of innovative therapies and a global commercial infrastructure.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated to be over $1.4 trillion and growing. Bristol-Myers Squibb is positioned to capture a significant share of this market through its diverse product portfolio and pipeline.
Upturn SWOT Analysis
Strengths
- Strong portfolio of established products
- Robust pipeline of novel therapies
- Global commercial infrastructure
- Strong financial position
Weaknesses
- Reliance on key products facing patent expirations
- High R&D costs
- Exposure to regulatory risks
- Integration challenges from acquisitions
Opportunities
- Expansion into new therapeutic areas
- Growth in emerging markets
- Strategic acquisitions and partnerships
- Advancements in personalized medicine
Threats
- Increasing competition from generic drugs and biosimilars
- Pricing pressures from healthcare payers
- Regulatory changes
- Unsuccessful clinical trials
Competitors and Market Share
Key Competitors
- MRK
- PFE
- JNJ
- ABBV
- AMGN
Competitive Landscape
Bristol-Myers Squibb faces intense competition from other large pharmaceutical companies. It competes on the basis of product innovation, pricing, and market access.
Major Acquisitions
MyoKardia
- Year: 2020
- Acquisition Price (USD millions): 13100
- Strategic Rationale: Expanded cardiovascular pipeline with mavacamten, a novel treatment for obstructive hypertrophic cardiomyopathy.
Growth Trajectory and Initiatives
Historical Growth: Bristol-Myers Squibb has experienced growth through product launches, acquisitions, and partnerships.
Future Projections: Analyst estimates project continued growth for Bristol-Myers Squibb, driven by new product launches and expansion in key markets.
Recent Initiatives: Recent initiatives include strategic acquisitions, pipeline development, and cost-cutting measures.
Summary
Bristol-Myers Squibb is a strong player in the pharmaceutical industry, with a diverse product portfolio and a robust pipeline. While facing patent expirations and competitive pressures, the company's strategic acquisitions and focus on innovation position it for continued growth. They need to focus on the new product pipeline and competition from companies that can take market share.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Analyst estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bristol-Myers Squibb Company
Exchange NYSE | Headquaters Princeton, NJ, United States | ||
IPO Launch date 1972-01-01 | CEO & Chairman Dr. Christopher S. Boerner Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 34100 | Website https://www.bms.com |
Full time employees 34100 | Website https://www.bms.com | ||
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.